ST3Gal I has been patented as a biomarker for predicting prognosis and/or monitoring progression of prostate cancer.147 ST3Gal I is also one of the genes identified in a 2014 patent that is expressed in circulating tumour cells and used to differentiate these cells from primary tumour cells, as well as being highlighted as a potential target to inhibit metastasis.148. The gene discussed is ST3GAL1; the disease is Familial prostate cancer.